Suri, Ajit <br/><br/>
Population PK and Exposure-Response Relationships for the Antibody-Drug Conjugate Brentuximab Vedotin in CTCL Patients in the Phase III ALCANZA Study.  [electronic resource] 

 -  Clinical pharmacology and therapeutics  11 2018 
 - 989-999 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1532-6535 
<br/><br/><label>Standard No.: </label>10.1002/cpt.1037  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Agents, Immunological--administration & dosage<br/>Brentuximab Vedotin<br/>Child<br/>Clinical Trials, Phase III as Topic<br/>Computer Simulation<br/>Dose-Response Relationship, Drug<br/>Drug Administration Schedule<br/>Drug Dosage Calculations<br/>Drug Monitoring<br/>Female<br/>Humans<br/>Immunoconjugates--administration & dosage<br/>Lymphoma, T-Cell, Cutaneous--blood<br/>Male<br/>Middle Aged<br/>Models, Biological<br/>Progression-Free Survival<br/>Risk Assessment<br/>Skin Neoplasms--blood<br/>Young Adult